DexCom (NASDAQ:DXCM) Announces Earnings Results

DexCom (NASDAQ:DXCM) announced its earnings results on Thursday. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09, FiscalAI reports. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.34%. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.48 earnings per share.

Here are the key takeaways from DexCom’s conference call:

• Positive Sentiment: Dexcom reported Q2 revenue of $1.31 billion, up 13% year over year, with international revenue rising 19%. Management raised full-year revenue guidance to $5.18–$5.25 billion and increased gross and operating margin outlooks.
• Positive Sentiment: The CONNECT trial showed a 1.6% A1C improvement among non-insulin type 2 diabetes patients, with 97% median CGM utilization. Dexcom believes the results could support broader commercial and Medicare reimbursement, including a potential CMS decision by year-end and coverage beginning in mid-2027.
• Positive Sentiment: G7 15-day adoption is tracking to plan, with nearly 50% of the U.S. customer base expected to convert by year-end. The product is now integrated with Tandem systems, has received Canadian regulatory clearance, and is contributing to stronger customer satisfaction and future margin expansion.
• Positive Sentiment: Strong execution drove non-GAAP gross margin to 64.1%, adjusted EBITDA margin to 32.2%, and more than $600 million of free cash flow in the first half. Dexcom repurchased approximately $600 million of stock in Q2 under its $1 billion 2026 authorization and completed its acquisition of Nutrisense to add personalized nutrition insights.
• Neutral Sentiment: Growth initiatives carry some near-term cost and execution considerations, including hiring and startup expenses for the Ireland manufacturing facility and approximately $15 million of second-half international revenue pressure from foreign exchange. Management expects gross margin to dip as Ireland production begins before leveraging over time.

DexCom Trading Up 12.0%

DXCM stock opened at $83.45 on Friday. DexCom has a 12 month low of $54.11 and a 12 month high of $87.00. The firm’s 50-day moving average is $73.14 and its 200 day moving average is $69.20. The company has a market capitalization of $32.20 billion, a PE ratio of 32.98, a P/E/G ratio of 1.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. Wells Fargo & Company upped their price target on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday. TD Cowen restated a “buy” rating on shares of DexCom in a research report on Friday. Robert W. Baird set a $105.00 target price on DexCom in a research report on Friday. Benchmark upped their target price on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday. Finally, Citigroup reiterated a “buy” rating and issued a $88.00 price target (up from $84.00) on shares of DexCom in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $88.12.

Insider Buying and Selling

In related news, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the transaction, the executive vice president directly owned 95,450 shares in the company, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,506 shares of company stock worth $7,205,258 over the last 90 days. Corporate insiders own 0.28% of the company’s stock.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the period. Vise Technologies Inc. purchased a new stake in DexCom in the fourth quarter worth about $208,000. DRW Securities LLC bought a new position in DexCom during the 4th quarter worth about $205,000. B. Riley Wealth Advisors Inc. bought a new position in DexCom during the 2nd quarter worth about $202,000. Finally, T. Rowe Price Investment Management Inc. increased its position in DexCom by 25.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,687 shares of the medical device company’s stock valued at $179,000 after purchasing an additional 538 shares during the period. 97.75% of the stock is owned by institutional investors.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.